Letermovir (GMP)
Letermovir (GMP) is the GMP grade of Letermovir. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Letermovir (GMP) is an orally active CMV inhibitor. Letermovir (GMP) targets the CMV terminase complex rather than CMV DNA polymerase and exerts its antiviral activity. Letermovir (GMP) can be used in the study of CMV infection[1].
Product Specifications
CAS Number
917389-32-3
Product Name Alternative
AIC246 (GMP) ; MK-8228 (GMP)
UNSPSC
12352005
Target
CMV
Related Pathways
Anti-infection
Applications
COVID-19-anti-virus
Field of Research
Infection
Smiles
FC1=C(N=C(N2CCN(C3=CC=CC(OC)=C3)CC2)N(C4=CC(C(F)(F)F)=CC=C4OC)[C@H]5CC(O)=O)C5=CC=C1
Molecular Formula
C29H28F4N4O4
Molecular Weight
572.55
References & Citations
[1]Lischka P, et al. In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246. Antimicrob Agents Chemother. 2010 Mar;54 (3) :1290-7.|[2]Wildum S, et al. In vitro drug combination studies of Letermovir (AIC246, MK-8228) with approved anti-human cytomegalovirus (HCMV) and anti-HIV compounds in inhibition of HCMV and HIV replication. Antimicrob Agents Chemother. 2015;59 (6) :3140-8.|[3]Marschall M, et al. In vitro evaluation of the activities of the novel anticytomegalovirus compound AIC246 (letermovir) against herpesviruses and other human pathogenic viruses. Antimicrob Agents Chemother. 2012 Feb;56 (2) :1135-7.|[4]Goldner T, et al. The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase. J Virol. 2011 Oct;85 (20) :10884-93.
Shipping Conditions
Room temperature
Scientific Category
GMP Small Molecules
Clinical Information
Phase 4
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
